Effect of gonadotropin-releasing hormone agonist treatment upon angiogenesis in uterine leiomyoma

被引:10
作者
Abulafia, O
Kleinhaus, K
Levi, G
Lee, YC
Sherer, DM
机构
[1] SUNY Hlth Sci Ctr, Dept Obstet & Gynecol, Div Gynecol Oncol, Brooklyn, NY 11203 USA
[2] SUNY Hlth Sci Ctr, Dept Pathol, Brooklyn, NY 11203 USA
[3] Maimonides Hosp, Brooklyn, NY 11219 USA
[4] Columbia Univ Coll Phys & Surg, St Lukes Roosevelt Hosp Ctr, Dept Obstet & Gynecol, New York, NY 10032 USA
关键词
angiogenesis; uterine leiomyoma; gonadotropin-releasing hormone agonist therapy;
D O I
10.1159/000052953
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To assess the effect of gonadotropin-releasing hormone (GnRH)agonist treatment upon angiogenesis in uterine leiomyomata. Methods: Uterine leiomyomata specimens of 49 consecutive patients who underwent myomectomy or hysterectomy following presurgical treatment with (n = 23) and without (n = 26) GnRH agonist were stained immunohistochemically with antibody to factor VIII-related antigen. For each subject, age, parity, number of Lupron treatments, leiomyoma size (cm), and mean microvessel counts calculated from three fields (x400) were recorded. Differences in patient age, parity, microvessel counts and leiomyoma size between GnRH agonist treated and untreated patients were tested by unpaired Student's t test. Differences among the various number of doses were tested by one-way ANOVA, with Bonferonni and Neuman-Keuls post hoc tests between specific dose-number groups. The relationship between microvessel counts and leiomyoma size was tested by Pearson correlation test. Multivariate stepwise regression tested the relationship between the number of Lupron doses and microvessel counts, correcting for age, parity, and leiomyoma size. p < 0.05 was considered significant. Results: Patient age and parity were similar in GnRH treated and untreated patients (mean 43.3 <plus/minus> 6.6 versus 43.9 +/- 7.5 years and median 2 (range 0-7) versus 1 (range 0-5), p = 0.78 and p = 0.45, respectively). Microvessel counts of leiomyomata specimens treated presurgically with GnRH agonist therapy (median 22.7, range 6.7-65.7) were not significantly different from microvessel counts of specimens without presurgical GnRH agonist treatment (median 19.8, range 6-53; p = 0.77). No correlation between leiomyoma size and microvessel counts was noted (r = 0.06, P = 0.7). Conclusion: Angiogenesis as assessed by microvessel counts in surgically removed leiomyomata is not affected by presurgical medical management with GnRH agonist therapy. Copyright (C) 2001 S. Karger AG, Basel.
引用
收藏
页码:108 / 113
页数:6
相关论文
共 27 条
[1]   Angiogenesis of the endometrium [J].
Abulafia, O ;
Sherer, DM .
OBSTETRICS AND GYNECOLOGY, 1999, 94 (01) :148-153
[2]   Angiogenesis of the ovary [J].
Abulafia, O ;
Sherer, DM .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2000, 182 (01) :240-246
[3]   Expression of the fibroblast growth factor receptor in women with leiomyomas and abnormal uterine bleeding [J].
Anania, CA ;
Stewart, EA ;
Quade, BJ ;
Hill, JA ;
Nowak, RA .
MOLECULAR HUMAN REPRODUCTION, 1997, 3 (08) :685-691
[4]  
BUTTRAM VC, 1981, FERTIL STERIL, V36, P433
[5]   THE HISTOPATHOLOGY OF UTERINE LEIOMYOMAS FOLLOWING TREATMENT WITH GONADOTROPIN-RELEASING-HORMONE ANALOGS [J].
COLGAN, TJ ;
PENDERGAST, S ;
LEBLANC, M .
HUMAN PATHOLOGY, 1993, 24 (10) :1073-1077
[6]   MORPHOLOGICAL-CHANGES IN UTERINE LEIOMYOMAS TREATED BY GNRH AGONIST GOSERELIN [J].
CROW, J ;
GARDNER, RL ;
MCSWEENEY, G ;
SHAW, RW .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1995, 14 (03) :235-242
[7]   Histology of leiomyomata in patients treated with leuprolide acetate [J].
Demopoulos, RI ;
Jones, KY ;
Mittal, KR ;
Vamvakas, EC .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1997, 16 (02) :131-137
[8]   Suppression of transforming growth factor-beta (TGF beta) and TGF beta receptor messenger ribonucleic acid and protein expression in leiomyomata in women receiving gonadotropin-releasing hormone agonist therapy [J].
Dou, QC ;
Zhao, Y ;
Tarnuzzer, RW ;
Rong, H ;
Williams, RS ;
Schultz, GS ;
Chegini, N .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (09) :3222-3230
[9]   Differential expression of matrix metalloproteinases and their tissue inhibitors in leiomyomata: a mechanism for gonadotrophin releasing hormone agonist-induced tumour regression [J].
Dou, QC ;
Tarnuzzer, RW ;
Williams, RS ;
Schultz, GS ;
Chegini, N .
MOLECULAR HUMAN REPRODUCTION, 1997, 3 (11) :1005-1014
[10]  
FOLKMAN J, 1986, CANCER RES, V46, P467